|Bid||0.00 x 1800|
|Ask||0.00 x 4000|
|Day's range||15.63 - 16.41|
|52-week range||11.75 - 31.82|
|Beta (5Y monthly)||0.83|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||0.91 (5.68%)|
|Ex-dividend date||12 May 2022|
|1y target est||18.50|
Royal Philips (NYSE: PHG) is promising a turnaround from its bottom-line woes, which began with one of the largest medical devices recalls in recent history. Two major factors explain the softness in Royal Philips' 2022 results: the ever-expanding recall of its subsidiary Philips Respironics' ventilators and sleep apnea masks, and continuing supply chain problems in the wake of the COVID-19 pandemic. There may be little the Netherlands-based company can do about component shortages, but the high-profile issues it faces due to defective sound abatement (noise reduction) foam in its breathing devices have no clear end.
AMSTERDAM (Reuters) -Dutch health technology company Philips' top management will not take any bonuses for 2022 after a global recall of respiratory devices resulted in a 70% plunge in the company's market value, it said on Tuesday. Given the company's performance and negative experience of shareholders and other stakeholders, the current management board has waived any 2022 annual incentive payouts, the company said in its annual report. "2022 was a very disappointing year for Philips and its stakeholders," it said.
CAMBRIDGE, Mass., February 20, 2023--Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that the company earned a spot on Forbes’ 2023 "America’s Best Large Employers" list. This is the fifth time that Philips has appeared in the ranking which is limited to 500 organizations across the country and just 15 in the Health Care Equipment & Services category.